x.com· @ · X·· 2026-04-23Score60
Reading
Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T
局部 nivolumab · Oral pre-cancer clinical response 85%, 1-year clearance 82%
Body
📋Investigators from @UTMDAnderson evaluated intralesional nivolumab in oral premalignant lesions in a first-in-human phase 1 trial. Their findings presented at #AACR26 included:
👉85% clinical response rate
👉21% pCR rate
👉60% median reduction in lesion area
👉No dose-limiting toxicities
#hncsm #AACR26 | @rsaddawi
Heat 3 · 2 likes · 0 replies · 1 repost
Conference abstracts
Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay
Read the abstract →Source: x.com · x.com